Success Metrics

Clinical Success Rate

100.0%

Based on 7 completed trials

Completion Rate

100%(7/7)

Active Trials

0(0%)

Results Posted

29%(2 trials)

Phase Distribution

Ph phase_1

40%

Ph phase_2

40%

Ph phase_3

20%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution10 total trials

Phase 1Safety & dosage

4(40.0%)

Phase 2Efficacy & side effects

4(40.0%)

Phase 3Large-scale testing

2(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

77.8%

7 of 9 finished

Non-Completion Rate

22.2%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(7)

Terminated(2)

Other(1)

Detailed Status

Completed7

Withdrawn2

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 14 (40.0%)

Phase 24 (40.0%)

Phase 32 (20.0%)

Trials by Status

withdrawn220%

completed770%

unknown110%

Recent Activity

0 active trials

Showing 5 of 10

completedphase_3

Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™

NCT03263026

completedphase_3

A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1

NCT03776071

completedphase_1

LY317615 Plus Capecitabine in Treating Patients With Advanced Solid Tumors

NCT00052273

completedphase_2

Enzastaurin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

NCT00407758

withdrawnphase_2

Enzastaurin, Carboplatin, and Gemcitabine With or Without Bevacizumab in Treating Patients With Recurrent, Stage IIIB, or Stage IV Non-Small Cell Lung Cancer

NCT00469976

View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials

NCT03263026Phase 3

Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™

Completed

NCT03776071Phase 3

A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1

Completed

NCT00052273Phase 1

LY317615 Plus Capecitabine in Treating Patients With Advanced Solid Tumors

Completed

NCT00407758Phase 2

Enzastaurin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Completed

NCT00469976Phase 2

Enzastaurin, Carboplatin, and Gemcitabine With or Without Bevacizumab in Treating Patients With Recurrent, Stage IIIB, or Stage IV Non-Small Cell Lung Cancer

Withdrawn

NCT00516607Phase 1

Enzastaurin and Temozolomide in Treating Patients With Primary Gliomas

Unknown

NCT00685633Phase 2

Bicalutamide With or Without Enzastaurin in Treating Patients With Prostate Cancer

Withdrawn

NCT00550927Phase 1

Enzastaurin and Bevacizumab in Treating Patients With Locally Advanced or Metastatic Cancer

Completed

NCT00503724Phase 1

Enzastaurin in Treating Young Patients With Refractory Primary CNS Tumors